NewLink/Merck Ebola vaccine 'ring' study starts in Guinea
This article was originally published in Scrip
Executive Summary
A Phase III trial testing an experimental recombinant vesicular stomatitis virus (rVSV) Ebola vaccine from NewLink Genetics and its partner Merck using a "ring" vaccination strategy got underway this week in Coyah prefecture, Guinea, the World Health Organization (WHO), which is sponsoring the study, said on 25 March.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.